ASO Author Reflections: Neoadjuvant Oxaliplatin Therapy for Peritoneal Carcinomatosis, Any Impact on Subsequent Hyperthermic Intraperitoneal Chemotherapy Perfusion?-Reference-Cited by-同舟云学术

ASO Author Reflections: Neoadjuvant Oxaliplatin Therapy for Peritoneal Carcinomatosis, Any Impact on Subsequent Hyperthermic Intraperitoneal Chemotherapy Perfusion?

Published:2023-01-05 Issue:4 Volume:30 Page:2494-2495
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Mangieri Christopher W.^ORCID,Levine Edward A.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-022-13009-7.pdf

Reference5 articles.

1. Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: management of appendiceal neoplasms. Cancer. 2020;126(11):2525–33. https://doi.org/10.1002/cncr.32881.

2. Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: management of colorectal metastases. Cancer. 2020;126(11):2534–40. https://doi.org/10.1002/cncr.32874.

3. Mangieri CW, Valenzuela CD, Solsky IB, Erali RA, Votanopoulos KI, Shen P, Levine EA. Exposure to neoadjuvant oxaliplatin-containing chemotherapy, does it effect intraperitoneal hyperthermic chemotherapy perfusion? Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-12933-y.

4. Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–66.

5. Votanopoulos KI, Mazzocchi A, Sivakumar H, Forsythe S, Aleman J, Levine EA, et al. Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: a feasibility study. Ann Surg Oncol. 2019;26(1):139–47.